Cancer heterogeneity is defined by normal cellular trade-offs

Weistuch, Corey, Murgas, Kevin A, Zhu, Jiening, Norton, Larry, Dill, Ken A, Deasy, Joseph O, Tannenbaum, Allen R (April 2023) Cancer heterogeneity is defined by normal cellular trade-offs. bioRxiv. (Submitted)

PDF 2023_Cancer_heterogeneity_is_defined_by_normal_preprint.pdf - Submitted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (866kB)

Abstract

Gene expression predicts tumor characteristics such as resistance to anticancer therapy. However, generalizing these predictors to multiple cancer types and data sets to motivate new therapeutic strategies has proven difficult. Here, we present a nonnegative matrix factorization (NMF) approach that decomposes gene expression into a universal set of "archetype" fingerprints. By restricting our analysis to five well-defined biological pathways, we show that trade-offs between normal tissues constrain oncogenic heterogeneity. Thus, the resulting six archetypes unify gene expression variation across 54 tissue types, 1504 cancer cell lines, and 1770 patient samples. The archetype mixtures correlate with cancer cell line sensitivity to several common anticancer therapies, even among cancers of the same type. They also explain subtype-specific breast cancer characteristics and define poor prognostic subgroups in breast, colorectal, and pancreatic cancers. Overall, the approach offers an evolvable resource for understanding commonalities across cancers, which could eventually lead to more robust therapeutic strategies.

Item Type:	Paper
Subjects:	diseases & disorders > cancer diseases & disorders
CSHL Authors:	Norton, Larry
Communities:	CSHL labs > Wigler lab
SWORD Depositor:	CSHL Elements
Depositing User:	CSHL Elements
Date:	13 April 2023
Date Deposited:	31 Oct 2023 20:04
Last Modified:	31 Oct 2023 20:04
PMCID:	PMC10120658
Related URLs:	Publisher
URI:	https://repository.cshl.edu/id/eprint/41287

Actions (login required)

Administrator's edit/view item